A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib in Combination with Paclitaxel as First-Line
Sponsor: |
Hoffmann-La Roche |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO6451 |
U.S. Govt. ID: |
NCT02322814 |
Contact: |
Jessica Segni: 212-305-0170 / js4686@columbia.edu |
The purpose of this study is to compare the effects, good and/or bad, of study drug cobimetinib and paclitaxel for patients with metastatic truple-negative breast cancer (mTNBC). In this study, you will receive either a combination of cobimetinib and paclitaxel or placebo (no active medication) and paclitaxel. The study will also evaluate what side effects cobimetinib and paclitaxel cause in patients.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Have you had prior chemotherapy, hormonal, or targeted therapy? |
Yes |
No |